Phase II data for apremilast in Behçet’s disease published
16 April 2015 | By Victoria White
Results from a multicentre, randomized, placebo-controlled phase II trial (BCT-001) of apremilast in patients with Behçet's disease have been published...
List view / Grid view
News
Active Biotech and Ipsen discontinue the development of prostate cancer drug tasquinimod
16 April 2015 | By Victoria White
Active Biotech and Ipsen discontinue the development of prostate cancer drug tasquinimod and have released top line results for the 10TASQ10 study...
Actelion initiates Phase III development of ponesimod for patients with relapsing MS
16 April 2015 | By Victoria White
Actelion has initiated Phase III development with ponesimod, its lead compound, in patients suffering from relapsing multiple sclerosis (MS)...
Melanoma treatment market value to more than quadruple to $5.64 billion by 2023, reports GlobalData
16 April 2015 | By Victoria White
The melanoma treatment market will increase from $1.34 billion in 2013 to $5.64 billion by 2023, representing a robust CAGR of 15.5%, reports GlobalData...
Positive clinical study results reported for évolis ONE – a hair growth product using novel FGF5 inhibitor
16 April 2015 | By Victoria White
Cellmid Limited has reported strong positive results in its independently conducted, blinded and placebo controlled human clinical study of évolis ONE...
Pivotal Phase 3 clinical trial of SGX203 in paediatric Crohn’s Disease given green light
15 April 2015 | By Victoria White
Soligenix and the FDA have reached an agreement on the design of a pivotal Phase 3 trial evaluating SGX203 in the treatment of paediatric Crohn’s disease...
Phase 2 clinical trial of Imprime PGG and bevacizumab achieved meaningful reductions in tumour burden
15 April 2015 | By Victoria White
The Phase 2 clinical trial of Imprime PGG and bevacizumab achieved meaningful reductions in tumour burden in patients with non-small cell lung cancer...
The global treatment market for Duchenne Muscular Dystrophy will expand to $990 million by 2019, says GlobalData
15 April 2015 | By Victoria White
The global treatment market for Duchenne Muscular Dystrophy will expand in value at a CAGR of 160.5% to $990 million by 2019, says GlobalData...
Pfizer announces IBRANCE Phase 3 PALOMA-3 trial met primary endpoint
15 April 2015 | By Victoria White
The Phase 3 PALOMA-3 trial for IBRANCE has been stopped early due to efficacy seen in women with HR+, HER2- metastatic breast cancer...
Swissmedic approves Lixiana for the prevention of stroke and systemic embolism in non-valvular atrial fibrillation
15 April 2015 | By Daiichi Sankyo
Swissmedic has granted approval of Lixiana for the prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation...
WHO calls for the disclosure of results from all clinical trials for medical products
15 April 2015 | By Victoria White
WHO has issued a public statement calling for the disclosure of results from clinical trials for medical products, whatever the result...
FDA agrees to Phase 3 clinical development programme of breakthrough antibiotic iclaprim
15 April 2015 | By Victoria White
The U.S. Food and Drug Administration (FDA) has agreed to the proposed Phase 3 clinical development programme for Motif’s lead product candidate, iclaprim...
European Regulatory Authority approves compassionate use of OMS721 in two patients with thrombotic microangiopathy
15 April 2015 | By Victoria White
The European Regulatory Authority has approved Omeros’ OMS721 for compassionate use in two patients with with thrombotic microangiopathy...
Incyte to establish European headquarters in Geneva
14 April 2015 | By Victoria White
Incyte's base for European clinical development operations is to be based in Geneva, Switzerland. Incyte is to occupy a 9,000 sq. ft. facility by mid-2015...
Merck Capacity Advancement Program to improve diabetes and hypertension healthcare capacity in Africa and Asia
14 April 2015 | By Victoria White
Merck is introducing diabetes management training for more than 5,000 Maharashtra University students as part of the Merck Capacity Advancement Program...
